Gene
ERCC6
ERCC6 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Actionable biomarkers (1), Trial mentions (11), Target-disease associations (170), and 5 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
4 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention ERCC6. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 2 of 8,738 | 0.02% | not measured | |
| 2025 | 1 of 8,875 | 0.01% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 1 of 11,460 | 0.01% |
| 2022 | 1 of 8,285 | 0.01% | 3 of 13,598 | 0.02% |
| 2021 | 0 of 8,692 | 0.00% | 3 of 15,045 | 0.02% |
| 2020 | 0 of 7,640 | 0.00% | 0 of 14,459 | 0.00% |
| 2019 | 1 of 7,300 | 0.01% | 7 of 12,159 | 0.06% |
| 2018 | 1 of 6,927 | 0.01% | 3 of 11,854 | 0.03% |
| 2017 | 0 of 6,558 | 0.00% | 3 of 11,595 | 0.03% |
Showing 10 of 37 years.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| ERCC6 oncogenic mutation | CISPLATIN | response-associated | ovarian carcinoma | Cancer Genome Interpreter |
Trial mentions (11)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT01142154 | Trial eligibility (AACT) |
| NCT04115072 | Trial eligibility (AACT) |
| NCT07057349 | Trial eligibility (AACT) |
| NCT07468604 | Trial eligibility (AACT) |
| NCT07577739 | Trial eligibility (AACT) |
Showing 5 of 11 trial mentions.
Target-disease associations (170)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Abruptio Placentae | pregnancy or perinatal disease | GWAS credible sets |
| Autosomal recessive cerebellar ataxia - blindness - deafness | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Autosomal recessive spastic paraplegia type 44 | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| COFS syndrome | disorder of visual system | Literature (Europe PMC) |
| COFS syndrome | disorder of visual system | Variant curation (ClinVar / EVA) |
Showing 5 of 170 associations.
Vendor sourcing (70)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | It is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.000004, PM2). The variant was observed in trans with a p... | View ClinVar record SCV002012042.1 |
| Albert Einstein College of Medicine | Trial sponsor | Mentioned in trial textTrial free-text mention | CSB | View trial NCT01028560 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein ... | View ClinVar record SCV003535840.2 |
| Astrazeneca Plc | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | #8) may have an ECOG Performance Status of ≤ 2. * Histological or cytological evidence/confirmation of urothelial cancer. * Metastatic and/or unresectable (c... | View trial NCT03448718 |
| Astrazeneca Plc | Trial collaborator | Mentioned in trial textTrial free-text mention | ERCC6 | View trial NCT03448718 |
Showing 5 of 70 sourcing records.
Trial-cited literature (32)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Balance telerehabilitation and wearable technology for people with Parkinson's disease (TelePD trial). | BMC neurology | 2023 | 17 |
| Genetic landscape of a large cohort of Primary Ovarian Insufficiency: New genes and pathways and implications for personalized medicine. | EBioMedicine | 2022 | 76 |
| Bacterial Signatures of Cerebral Thrombi in Large Vessel Occlusion Stroke. | mBio | 2022 | 17 |
| DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination. | Frontiers in oncology | 2022 | 12 |
| The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. | Nature communications | 2021 | 99 |
Showing 5 of 32 papers.
Protein variant mentions (52)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A1215T | 1 | 2015 | PMID 25741868 |
| p.C766F | 1 | 2015 | PMID 25741868 |
| p.D1355E | 1 | 2015 | PMID 25741868 |
| p.D425A | 2 | 2015 to 2022 | PMID 36099812, PMID 25741868 |
| p.D639G | 1 | 2015 | PMID 25741868 |
Showing 5 of 52 variants.
Literature-extracted relations (4)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Primary Ovarian Insufficiency | Disease | associate |
Genetic landscape of a large cohort of Primary Ovarian Insufficiency: New genes and pathways and implications for personalized medicine. | 2022 |
| Cockayne Syndrome | Disease | associate |
Ending a diagnostic odyssey: Moving from exome to genome to identify cockayne syndrome. | 2021 |
| Nervous System Diseases | Disease | associate |
Ending a diagnostic odyssey: Moving from exome to genome to identify cockayne syndrome. | 2021 |
| Neoplasms | Disease | associate |
Somatic mutations in early onset luminal breast cancer. | 2018 |
Organizations publishing (63)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 2 | 2009 to 2010 |
| Oregon Health & Science University | Academic | 2 | 2009 to 2023 |
| Rady Children's Institute for Genomic Medicine | Nonprofit | 2 | 2019 to 2021 |
| University of Guelph | Academic | 2 | 2019 to 2021 |
| Aix-Marseille Université | Academic | 1 | 2022 |
Showing 5 of 63 organizations.
Where ERCC6 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of ear
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- measurement
- nervous system disease
- phenotype
- pregnancy or perinatal disease
144 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, assay-provider ledger, and human sample screening reference.